The Missing Role in Every Virtual and Small Biotech

Who Owns CMC When There Is No Internal Team?

1. The Case for Fractional CMC Leadership

Virtual and small biotechs occupy a broad spectrum of strategic objectives. Some are advancing a molecule toward commercial launch. Others are building to a partnering event, a licensing transaction, or an acquisition at a clinical readout. Still others are pursuing commercial launch across multiple life-science markets. Across all of these paths, the CMC program must be structured, owned, and executed to a standard that supports the program’s regulatory and strategic objectives at every stage.

Fractional CMC leadership is the model that makes this possible for organizations without the internal headcount to staff a senior development function. It provides the program ownership, technical depth, regulatory strategy, and commercial awareness of a VP of Development at a cost structure calibrated to the capital constraints of a development-stage organization. It is not a substitute for eventual internal team-building; it is the bridge that protects the program and the asset while that team is being built.

Fractional CMC leadership is not project management. A project manager tracks progress against a defined scope, monitors milestones, and manages schedule and resource allocation. In that role, the technical direction, the regulatory strategy, and the soundness of the decisions being executed are assumed. A fractional CMC leader defines the scope, sets the technical direction, and makes or directly informs the decisions that determine whether the program is on the right path — in addition to directing progress along it. This distinction matters most at the moments it is hardest to see: when a Phase 1 program is executing smoothly against a plan that was not designed for Phase 2, or when a specification is being met by a process that will not survive the transition to commercial manufacturing. A project manager tracks those milestones as green. A fractional CMC leader identifies the underlying problem before it surfaces.

The value of fractional CMC leadership is most clearly understood in the context of what it provides that no other resource in the typical virtual biotech structure provides: accountability to program outcomes. A CRO is accountable for study execution. A CMO or CDMO is accountable for manufacturing and development deliverables within a contracted scope. Regulatory counsel is accountable for submission strategy and filing. IP counsel is accountable for freedom-to-operate and patent strategy. Quality is accountable for compliance. None of these is accountable for the integration of these workstreams into a coherent program that advances the asset on schedule and protects its value. That integration is CMC program leadership — and in the absence of an internal team, it belongs to a fractional CMC leader.

In our experience, virtual and small biotechs that engage fractional CMC leadership before CMO selection, before the development scope is set, and before the first IND-enabling studies begin demonstrate more efficient use of development capital, fewer costly program corrections, and stronger CMC packages at regulatory submission and partnering due diligence than those that rely on CMO or CDMO execution alone.

2. What CMOs and CDMOs Provide — and What They Do Not

Contract manufacturers execute manufacturing operations to the specifications, processes, and quality standards defined by the sponsor. CDMOs extend this by offering development services alongside manufacturing. Both provide significant value and are essential partners in any virtual biotech development program.

A CMO or CDMO is accountable for the deliverables defined in its statement of work. It is not accountable for the program strategy, the regulatory direction, or the integration of its work into the sponsor’s broader development objectives. It executes against direction. It does not provide the direction.

A CDMO will optimize for what is in scope and what is technically achievable within the contracted program. Without senior CMC oversight, this commonly results in processes and specifications designed for the immediate objective — Phase 1 or IND-enabling work — without adequate consideration of the technical standards required at later development stages, the commercial manufacturing requirements, or the regulatory defensibility of the data package being generated. The gaps this creates surface at the transitions between development phases, at IND submission, and at NDA filing or partnering due diligence, precisely when timelines are most sensitive and capital is most constrained.

The following program responsibilities fall outside CMO and CDMO scope and must be owned internally or by a designated fractional CMC leader:

• Accountability for the overall success of the development program and the strategic value of the asset — whether the objective is commercial launch, licensing, partnering, or acquisition
• Regulatory CMC strategy — determining what the IND and subsequent submissions require, how CMC sections should be structured, and how development work should be documented; this work proceeds in parallel with development, not after it
• IND and NDA CMC module preparation — authoring and coordinating CMC sections of regulatory submissions in collaboration with regulatory affairs leads
• Specification setting and justification — establishing specifications that reflect process understanding, support the regulatory strategy, and do not unnecessarily constrain the commercial or partnering program
• Analytical method strategy and transfer oversight — determining what methods are required and how they will be transferred; while many CDMOs perform analytical development as a contracted workstream, the strategic oversight ensuring methods are fit for regulatory submission and future site transfer remains a sponsor responsibility
• Batch record review, deviation management, and quality decisions — review and disposition of manufacturing and development documentation
• IP strategy and technology protection — identifying what information can be shared with a CMO and how the CMO agreement should be structured to preserve technology ownership; inadequate IP protection at this stage can materially reduce asset value regardless of the intended exit strategy
• Long-term strategy translated into tactical program objectives — ensuring near-term development decisions are aligned with clinical, regulatory, commercial, and partnership objectives
• Technology capture and protection for future transfer — capturing process knowledge in a form that supports future technology transfer to a commercial or partner manufacturing site
• Program schedule and priorities — integrating CMC workstreams into the master development timeline and managing trade-offs when competing priorities create schedule pressure

These workstreams require a party accountable to the sponsor’s program goals and outcomes — not to the deliverables in a contract manufacturer’s statement of work. Fractional CMC leadership fills this role.

3. The Cost of an Unowned CMC Program

Industry data on clinical-stage pharmaceutical development consistently identifies CMC-related issues as a leading cause of regulatory delay, clinical hold, and NDA remediation. For virtual and small biotechs operating with seed or Series A capital, the financial and timeline consequences of CMC program gaps are disproportionately severe relative to the cost of preventing them.

• IND delays occur when data packages do not support the submission as structured because the regulatory strategy was not defined before the development work started. The result is multiple months of added timeline and, in many cases, significant analytical and manufacturing rework. For a development-stage organization, a multi-month IND delay affects not only the clinical timeline but the financing cycle, effective commercial exclusivity period, firm valuation, and partnership discussions that depend on it.
• Specification revision after IND submission is triggered when specifications established without adequate process understanding must be changed, producing amendments and agency interactions that were not planned for. When revisions require supporting development work — additional stability studies, analytical method updates, process characterization — the timeline and capital impact compounds significantly.
• Phase 1 to Phase 2 CMC remediation represents the most consequential and least visible gap. This gap does not surface during Phase 1 execution. It surfaces at the transition, when the process must be characterized to a higher standard, specifications must be tightened and justified, and manufacturing scale typically increases. Programs that encounter this gap frequently require six to twelve months of additional CMC work before Phase 2 can proceed. This occurs precisely when the clinical program is ready to advance. The delay is preventable and attributable entirely to CMC design decisions made at the beginning of the program.
• CMO transitions mid-program — typically necessitated by a CMO selected for Phase 1 that lacks the capacity or capability for Phase 2 or commercial scale — add technology transfer timelines, qualification studies, and regulatory notifications that are manageable when anticipated and highly disruptive when not.
• IP exposure resulting from inadequate contractual protection of proprietary process knowledge transferred to a CMO can reduce the asset’s commercial and partnership value in ways that are difficult or impossible to recover.

The cost of fractional CMC leadership engaged from program initiation is a fraction of the cost of any one of these outcomes. A CMC program with documented gaps, unresolved specifications, and inadequate analytical method validation increases cost, extends timeline, and reduces asset valuation in due diligence — regardless of the clinical data.

4. The Fractional Leadership Model in Practice

The fractional CMC leadership model provides senior development and program management expertise at a defined and adjustable time commitment, calibrated to the program stage and the specific workstreams requiring ownership at each phase.

Fractional CMC leadership means active participation in the program: attending technical and cross-functional meetings, owning defined workstreams, collaborating with regulatory affairs, clinical, quality, finance, and executive functions, and remaining accountable to the same program milestones and timelines that the board and investors track. The engagement is embedded in program execution, not advisory. Deliverables are program outcomes, not standalone reports.

Workstreams covered in a typical early-stage engagement:

• CMO and CDMO evaluation, selection criteria development, and ongoing relationship management
• Development program design — defining what work needs to be done, in what sequence, and to what standard, with phase transition requirements in view from the outset
• Regulatory CMC strategy — structuring the development program to produce data and documentation required for IND submission, Phase 2 advancement, and NDA filing or partnering due diligence; executed in collaboration with regulatory affairs leads
• Analytical method strategy — defining method requirements, overseeing development and validation, and ensuring methods are structured for regulatory submission and future transfer
• Specification development — establishing specifications grounded in process understanding that support the regulatory strategy and do not unnecessarily constrain commercial manufacturing or partnership discussions
• Quality system integration — evaluating the CMO’s quality systems against program requirements and ensuring appropriate oversight mechanisms are in place
• IP and technology protection — identifying proprietary elements requiring contractual protection and ensuring CMO agreements are structured accordingly
• Program scheduling and priority management — integrating CMC workstreams into the master development timeline and managing competing priorities as the program advances

Engagement levels can increase as the program advances through IND-enabling studies, Phase 1 execution, and the Phase 2 transition, without the fixed cost structure of a full-time senior hire. At a stage when capital efficiency is paramount, this flexibility is material. As internal team capacity develops, the fractional engagement is reduced in a structured transition that transfers institutional knowledge, documented processes, and program continuity to the internal team.

5. CMC Requirements Across Development Phases

The phase-appropriate CMC standard and the transition requirements between phases provide the technical context for understanding when fractional CMC oversight is most consequential and what the cost of deferred decisions actually is.

Phase 1: Establishing the Foundation

At Phase 1, the CMC package is expected to support patient safety in a small study population, not to represent the commercial program. Requirements include GMP manufacturing, preliminary specifications supported by available process and analytical data, analytical methods suitable for their intended use, and stability data sufficient to cover the clinical use period.

At this stage, the fractional CMC leader defines the development program architecture: establishing the synthesis route strategy, setting the analytical method framework, selecting and qualifying the CMO, drafting the specification strategy, and ensuring the regulatory CMC strategy is in place before IND-enabling work begins. The permissive Phase 1 regulatory standard creates a decision window that, used correctly, reduces downstream risk significantly. Used without structured CMC oversight, it defers problems to the Phase 1 to Phase 2 transition, when they are far more expensive to resolve.

Phase 1 to Phase 2: The Highest-Cost CMC Transition

Expectations increase materially at Phase 2. Process understanding must deepen, specifications must be tightened and better justified, analytical methods must advance toward full validation, and manufacturing scale typically increases, potentially requiring technology transfer to a new site if the Phase 1 CMO is not the organization that will manufacture Phase 2 or commercial material.

At this transition, the fractional CMC leader manages the gap assessment between what the Phase 1 program produced and what Phase 2 requires: identifying specification revisions needed, advancing analytical method validation, coordinating technology transfer if a CMO change is required, and ensuring the CMC package being assembled is defensible in the context of the eventual regulatory submission. Phase 2 clinical material forms part of the NDA package. The fractional CMC leader ensures the manufacturing and analytical processes generating that material are structured and documented to that standard from the outset of Phase 2, not retrospectively.

Phase 2 to Phase 3: Approaching the Commercial Standard

CMC expectations at Phase 3 are substantially equivalent to the commercial standard: the manufacturing process must be essentially final; specifications must be at or near proposed commercial values; analytical methods must be fully validated; and the commercial manufacturing site must be identified and, in most cases, must be producing the Phase 3 material, or comparability must be formally established.

At this stage, the fractional CMC leader ensures that the process validation strategy is defined and in execution, that the commercial manufacturing site has been selected and is being qualified in parallel with Phase 3 clinical execution, and that the CMC sections of the NDA are being assembled from the development history documented and maintained throughout the program. For programs with a partnering or licensing objective, the fractional CMC leader ensures the CMC data room is organized, complete, and represents the manufacturing program as credibly as the clinical data package.

The table below summarizes FDA’s phase-appropriate CMC expectations and what a fractional CMC leader must be structured to deliver at each transition.

6. When to Engage — and Why Timing Matters

Delayed engagement of CMC program leadership is a costly error. Virtual and small biotechs that initiate fractional CMC engagement after CMO selection, after the development scope has been defined, and after the first IND-enabling studies have begun have already made foundational program decisions under conditions of limited oversight. Correcting those decisions requires effort and capital that earlier engagement would have avoided.

The highest-value engagement point is before the decisions that define the program’s regulatory and IP pathway: synthesis route strategy, starting material qualification, analytical method framework, and manufacturing partner selection. These decisions, made together in the early weeks of a development program, constrain every subsequent stage.

The synthesis route strategy alone shapes the program for its entire development life. It determines whether a route must be developed or optimized, what starting material qualification standard applies, how the impurity profile will be managed, and how the approach fits within the regulatory, timeline, and budget framework. Senior CMC oversight at this stage costs a fraction of what it costs to revisit these decisions once work has begun.

Decisions requiring senior CMC involvement from program initiation:

• Synthesis route strategy — determining whether a route needs to be developed or optimized, what starting material qualification requirements apply, how the impurity profile will be managed, and how the approach aligns with the regulatory, timeline, and budget framework
• Analytical method framework — identifying what methods are required, what platform capabilities exist at candidate CMOs, what will need to be developed, and how the method program should be structured to support regulatory submissions and future site transfers
• CMO and CDMO evaluation — assessing not only capability for the current development stage but capacity, technology transfer compatibility, and strategic fit for Phase 2 and commercial or partner manufacturing
• Specification strategy — determining which specifications must be established now, which may be deferred, and how to structure specifications that support the regulatory strategy without unnecessarily constraining process development or subsequent program objectives
• IP protection strategy — defining what information may be shared with manufacturing partners, what requires protection, and how CMO agreements should be structured to preserve technology ownership and asset value

The Phase 1 to Phase 2 transition represents the second critical engagement point. At this stage, process understanding requirements increase, regulatory expectations shift, manufacturing scale changes, and the gaps in early-stage CMC program design become visible simultaneously. Fractional CMC leadership engaged prior to or at this transition provides the technical and regulatory continuity required to manage its complexity effectively, and to avoid the six to twelve months of additional CMC work that programs without that continuity frequently require before Phase 2 can proceed.

7. Criteria for Selecting a Fractional CMC Partner

Fractional CMC consulting engagements vary substantially in depth of technical experience, regulatory knowledge, and program management capability. The following criteria are relevant to evaluating fit and capability for a development-stage program:

• Direct, hands-on CMC program leadership across multiple development stages — direct ownership of CMC programs through IND submission, Phase 1 and Phase 2 execution, and commercial manufacturing transition or partnership due diligence; including access to a network of specialist partners for workstreams requiring capabilities outside the core engagement scope
• Regulatory CMC experience — familiarity with IND, NDA, and where applicable international regulatory submission requirements, and the ability to work collaboratively with regulatory affairs leads to structure development work that supports regulatory submissions; the fractional CMC leader is not the regulatory lead but must be capable of driving the CMC program to a standard that regulatory submissions can be built on
• Established working knowledge of the CMO and CDMO ecosystem — understanding of organizational capabilities, capacity, and technical fit that enables more informed partner selection and more effective ongoing oversight
• Organizational scalability — the ability to adjust the level and composition of engagement as the program advances, increasing involvement at key inflection points and stepping back as internal team capacity grows, without disruption to program continuity
• IP and technology transfer expertise — experience identifying protectable elements of a development program, structuring CMO agreements to preserve sponsor ownership, and executing technology transfers in a manner that maintains process integrity and regulatory continuity
• Commercial and competitive awareness — understanding where the molecule sits relative to competing programs and marketed products, and how CMC decisions made during development affect commercial manufacturability, cost of goods, market positioning, and partnership or licensing value

CMC decisions can satisfy regulatory requirements while undermining commercial objectives. A synthesis route may be technically sound but unmanufacturable at commercial scale at acceptable cost. A Phase 1 formulation may not support the patient population or administration route required for commercial or partnering success. A stability program may meet regulatory requirements while creating supply chain constraints that limit market access or reduce asset attractiveness in a licensing transaction. Technical expertise alone does not catch these problems. Strategic awareness does.

A fractional CMC partner with both technical depth and strategic awareness provides the perspective required to ensure that development decisions serve the program’s ultimate objectives regardless of the intended exit.

Conclusion: Program Ownership as a Value Creation Strategy

The virtual and small biotech model is now the standard approach for advancing development-stage programs across a range of strategic objectives: from independent commercial development to partnering, licensing, and acquisition. CDMOs have substantially expanded the development and manufacturing capabilities available to organizations without internal infrastructure.

Fractional CMC leadership completes the model. It provides the program ownership, regulatory strategy integration, and commercial awareness that CMO and CDMO relationships are not structured to provide, at a cost structure appropriate to the capital stage of the organization that needs it. The workstreams it covers are not peripheral — they are the workstreams that determine whether a program reaches regulatory submission on schedule, advances through clinical development without costly remediation, and arrives at NDA submission or a partnering data room with a CMC package that supports the program’s objectives.

Capital deployed toward qualified CMC program leadership at program initiation advances the science, protects the asset, and reduces the cost of the delays and rework that consume development budgets in programs without it. It is not an overhead cost. It is a risk-adjusted investment in the value of the program itself.

---

Back to Technical Insights